Figure 6.

CD56⁺ILC1-like cells are present in NK-cell preparations used for NK-cell transfer therapy. (A) Representative density plots of the extracellular flow cytometry panel used to identify the ILC subsets in CD3⁻ CD56⁺-enriched fractions of HD PBMCs. (B) Proportions of total ILCs (Lineage⁻CD127⁺), CD56^bright CD16⁻, and CD56^dim CD16⁺ NKs in NK-cell transfer therapy products from HD PBMCs (n = 10). (C) NK marker expression on PB CD56⁺ ILC1-like cells before and after the CD3⁻ CD56⁺ enrichment (n = 5).